Cargando…

Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate

As one of the major therapeutic options for cancer treatment, chemotherapy has limited selectivity against cancer cells. Consequently, this therapeutic strategy offers a small therapeutic window with potentially high toxicity and thus limited efficacy of doses that can be tolerated by patients. Anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheyi, Rotimi, de la Torre, Beatriz G., Albericio, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874516/ https://www.ncbi.nlm.nih.gov/pubmed/35214128 http://dx.doi.org/10.3390/pharmaceutics14020396

Ejemplares similares

s-Triazine: A Privileged Structure for Drug Discovery and Bioconjugation
por: Sharma, Anamika, et al.
Publicado: (2021)

Perfluorophenyl Derivatives as Unsymmetrical Linkers for Solid Phase Conjugation
por: Alapour, Saba, et al.
Publicado: (2018)

Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016)

Antibody–drug conjugates: Recent advances in linker chemistry
por: Su, Zheng, et al.
Publicado: (2021)

Lysosomal-Cleavable Peptide Linkers in Antibody–Drug Conjugates
por: Balamkundu, Seetharamsing, et al.
Publicado: (2023)

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
por: Donaghy, Heather
Publicado: (2016)

Linkers Having a Crucial Role in Antibody–Drug Conjugates
por: Lu, Jun, et al.
Publicado: (2016)

Sulfatase-cleavable linkers for antibody-drug conjugates
por: Bargh, Jonathan D., et al.
Publicado: (2020)

Peroxide-cleavable linkers for antibody–drug conjugates
por: Ashman, Nicola, et al.
Publicado: (2023)

The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2022)

The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2018)

The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: G. de la Torre, Beatriz, et al.
Publicado: (2019)

The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2020)

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2021)

The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2023)

The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type
por: de la Torre, Beatriz G., et al.
Publicado: (2017)

Exploring the Orthogonal Chemoselectivity of 2,4,6-Trichloro-1,3,5-Triazine (TCT) as a Trifunctional Linker With Different Nucleophiles: Rules of the Game
por: Sharma, Anamika, et al.
Publicado: (2018)

Chemical Conjugation in Drug Delivery Systems
por: Eras, Alexis, et al.
Publicado: (2022)

Impact of linker-drug on ion exchange chromatography separation of antibody-drug conjugates
por: Zhang, Zhaorui, et al.
Publicado: (2019)

Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody–Drug Conjugates for Cancer Therapy
por: Johan, Audrey Nathania, et al.
Publicado: (2022)

Acid-cleavable thiomaleamic acid linker for homogeneous antibody–drug conjugation
por: Castañeda, Lourdes, et al.
Publicado: (2013)

Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
por: Conilh, Louise, et al.
Publicado: (2021)

A light-responsive, self-immolative linker for controlled drug delivery via peptide- and protein-drug conjugates
por: Zang, Chuanlong, et al.
Publicado: (2019)

Computational Construction of Antibody–Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable Linker
por: Filntisi, Arianna, et al.
Publicado: (2014)

An Efficient Conjugation Approach for Coupling Drugs to Native Antibodies via the Pt(II) Linker Lx for Improved Manufacturability of Antibody–Drug Conjugates
por: Merkul, Eugen, et al.
Publicado: (2021)

On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency
por: Dovgan, Igor, et al.
Publicado: (2020)

Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate
por: Puthenveetil, Sujiet, et al.
Publicado: (2017)

Improving Antibody‐Tubulysin Conjugates through Linker Chemistry and Site‐Specific Conjugation
por: Hamilton, Joseph Z., et al.
Publicado: (2021)

Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced in vivo Performance
por: Evans, Nick, et al.
Publicado: (2022)

Antibody Drug Conjugate Bioinformatics: Drug Delivery through the Letterbox
por: Vlachakis, Dimitrios, et al.
Publicado: (2013)

Design and Validation of Linkers for Site-Specific Preparation of Antibody–Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site
por: Kumar, Amit, et al.
Publicado: (2020)

Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice
por: Anami, Yasuaki, et al.
Publicado: (2018)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics
por: Kumari, Mamta, et al.
Publicado: (2023)

Aptamer–Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells
por: Qi, Jianjun, et al.
Publicado: (2022)

Improving the Serum Stability of Site-Specific Antibody Conjugates with Sulfone Linkers
por: Patterson, James T., et al.
Publicado: (2014)

Naturally Occurring Oxazole-Containing Peptides
por: Mhlongo, Jessica T., et al.
Publicado: (2020)

Construction of paclitaxel-based antibody–drug conjugates with a PEGylated linker to achieve superior therapeutic index
por: Shao, Ting, et al.
Publicado: (2020)

A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
por: Perez Bay, Andres E., et al.
Publicado: (2023)

Practical Protocols for Solid-Phase Peptide Synthesis 4.0
por: de la Torre, Beatriz G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1cr0uc5p9krflsd5pa5vd4ngbb